RxDoctor Payments Data

Allaix Philogene, MD

Internal Medicine · Bell Glade, FLNPI 1851490379

Payments from drug & device makers

$1,228in general payments, 2019–2025

Across 43 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$572
  • Gilead$195
  • Novartis$138
  • GSK$112
  • Pfizer$96
  • Janssen Products, LP$96
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$1,21499%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,228 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$42,884
Medicare patients
43
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine52$153,323
TriumeqAbacavir/Dolutegravir/Lamivudi16$62,294
TradjentaLinagliptin34$24,952
OzempicSemaglutide15$22,906
EliquisApixaban32$22,207
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen338$9,870
XareltoRivaroxaban11$9,507
MyrbetriqMirabegron11$8,224
SymbicortBudesonide/Formoterol Fumarate21$6,603
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro16$4,060
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm18$2,272
Megestrol Acetate19$2,162
Comfort Ez Pen NeedlePen Needle, Diabetic18$2,039
Albuterol Sulfate HfaAlbuterol Sulfate54$1,921
Famotidine52$1,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Triumeq$572$215,61868 claims
PfizerEliquis$96$22,20732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bell Glade

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →